Matthew R. Thompson
A5075954345- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Computational Drug Discovery Methods
- Peptidase Inhibition and Analysis
- CRISPR and Genetic Engineering
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Ubiquitin and proteasome pathways
- Cell death mechanisms and regulation
- Patient Safety and Medication Errors
- Immune Cell Function and Interaction
- RNA regulation and disease
- Immune Response and Inflammation
- Immune cells in cancer
- Receptor Mechanisms and Signaling
- Electronic Health Records Systems
- Clinical practice guidelines implementation
- Phagocytosis and Immune Regulation
- Adenosine and Purinergic Signaling
- Teacher Education and Leadership Studies
- Mentoring and Academic Development
- Protein Kinase Regulation and GTPase Signaling
- Labor market dynamics and wage inequality
- Counseling Practices and Supervision
Caribou Biosciences (United States)
2024
Weatherford College
2023
Monash University
2009-2017
Hudson Institute of Medical Research
2017
Monash Institute of Medical Research
2009-2013
Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory multiple myeloma. is a...
Abstract Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non–small cell lung cancer, estrogen receptor–positive breast trials underway assessing their combination regimens including immunotherapy. However, there is currently no clear strategy to reliably predict HDACi sensitivity. In colon cancer...
Macrophages play an essential role in the innate immune response to infection and tissue injury. However, excessive macrophage activation may also significantly contribute chronic inflammatory diseases. The Toll-like receptor (TLR) family are key regulators of responses macrophages, they able promote their survival resistance against apoptosis. We, others, have shown that adaptive gene, activating transcription factor 3 (ATF3), acts as a negative regulator TLR signaling by repressing...
This article describes the rationale, processes, technology, and results of creating a paper-based rounds report that is now used by our entire institution for efficient inpatient work checkout are routinely done in virtually every hospital, both academic private, US. The survey clinicians suggests printed reports have markedly improved rounding efficiency, saved substantial amounts physician time, standardized patient safety.
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>CB-011 immune-cloaking armoring strategy suppresses cytotoxic T and NK cell–mediated allograft rejection.</p>
<p>In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.</p>
<p>Gamma-secretase inhibitor RO4929097 increases BCMA expression on-target cell lines but does not improve CB-011 antitumor efficacy.</p>
<p>CB-011 cells exhibit in vitro antitumor activity against PBMCs from patients with multiple myeloma.</p>
<div>Abstract<p>Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory...
<p>CB-011 immune-cloaking armoring strategy reduced NK cell proliferation and CAR+ T stress signatures.</p>
<div>Abstract<p>Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of challenges associated with patient-derived (autologous) CAR cells. Key considerations in development allogeneic include prevention graft-vs-host disease (GvHD) and suppression allograft rejection. Here, we describe preclinical data supporting ongoing first-in-human clinical study, CaMMouflage trial (NCT05722418), evaluating CB-011 patients relapsed/refractory...
<p>In vitro serial rechallenge assay demonstrates long-term cytotoxicity activity of CB-011 against BCMA+ tumor cells.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>CB-011 immune-cloaking armoring strategy suppresses cytotoxic T and NK cell–mediated allograft rejection.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>
<p>chRDNA-mediated gene editing did not result in any off-target above the limit of detection.</p>
<p>chRDNA-mediated gene editing did not result in any off-target above the limit of detection.</p>
<p>Gamma-secretase inhibitor RO4929097 increases BCMA expression on-target cell lines but does not improve CB-011 antitumor efficacy.</p>
<p>CB-011 cells exhibit in vitro antitumor activity against PBMCs from patients with multiple myeloma.</p>
<p>Antitumor activity of CB-011 CAR-T cells in a xenograft model multiple myeloma.</p>